Strategic Alliances and Collaborations
- Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
- Alnylam Pharmaceuticals in its collaboration with Regeneron Pharmaceuticals for new RNA interference therapeutics focused on ocular and central nervous system diseases with deal value up to $1 billion
- AMAG in its strategic collaboration with Endoceutics to develop and commercialize Intrarosa, with a potential deal value of up to $945 million
- Arrakis Therapeutics in its strategic collaboration and license agreement with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas, for $190 upfront
- BeiGene in its global research and development collaboration with Ambrx to develop novel biologic drug products with aggregate value of up to $475 million
- Blueprint Medicine in its worldwide collaboration with Roche for up to five small molecule kinase therapeutics for cancer immunotherapy; upfront of $45 million with total deal value of up to $965 million
- BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
- ImmuNext in its exclusive, worldwide license with Sanofi to develop and commercialize a CD40L monoclonal antibody for use in autoimmune diseases, with potential deal value of up to $500 million, plus royalties
- Immunometabolism Development Company in a licensing transaction with potential deal value of up to $605 million
- Kymera Therapeutics in its strategic collaboration with Vertex to advance small molecule protein degraders against multiple biological targets, with potential deal value in excess of $1 billion
- Moderna Therapeutics in multiple strategic transactions with AstraZeneca, Merck and others with total upfront deal value in excess of $1 billion, plus downstream payments
- Obsidian Therapeutics in its strategic collaboration with Celgene to develop novel, regulated cell therapies using Obsidian’s destabilizing domain technology
- Scholar Rock in its strategic collaboration with Gilead to develop TGFβ inhibitors with potential total deal value of up to $1.5 billion
- Surface Oncology in its strategic collaboration with Novartis to develop immunotherapeutics; up to $170 million in near-term cash payments, plus milestones and royalties
- Unum Therapeutics in its strategic collaboration and license agreement with Seattle Genetics to develop and commercialize ACTR therapies for cancer, with a total potential deal value of over $640 million, plus royalties
- Wave Life Sciences in its global strategic collaboration with Takeda for nucleic acid therapies for CNS disorders, with potential deal value of over $2 billion
M&A
- BlueRock Therapeutics in its sale to Bayer AG for up to $1 billion
- Nimbus in its long-term strategic alliance with Celgene to acquire two programs in immunology
- Nimbus in its sale of Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead Sciences for $400 million and up to an additional $800 million in development milestone payments
- Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
- TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
- TARIS Biomedical in its acquisition by Johnson & Johnson
- ZOLL Medical in its sale to Asahi Kasei for $2.2 billion
